Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Invested Capital (2019 - 2025)

Keros Therapeutics' Invested Capital history spans 7 years, with the latest figure at $303.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 46.96% year-over-year to $303.1 million; the TTM value through Dec 2025 reached $303.1 million, down 46.96%, while the annual FY2025 figure was $303.1 million, 46.96% down from the prior year.
  • Invested Capital reached $303.1 million in Q4 2025 per KROS's latest filing, down from $703.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $728.9 million in Q1 2025 to a low of $211.2 million in Q2 2022.
  • Average Invested Capital over 5 years is $381.5 million, with a median of $314.7 million recorded in 2023.
  • Peak YoY movement for Invested Capital: soared 1098.8% in 2021, then plummeted 46.96% in 2025.
  • A 5-year view of Invested Capital shows it stood at $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then crashed by 46.96% to $303.1 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Invested Capital are $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025).